Update on Statins: 2003

Vaughan, Carl J.; Gotto, Antonio M.

doi:10.1161/01.cir.0000139312.10076.ba

Cited by 213 publications

(171 citation statements)

References 66 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…The risk of myopathy is increased with high doses [3]. The mechanism determining muscle damage is not clear [6]. There are several possible mechanisms such as depletion of secondary metabolic intermediates and induction of apoptosis, have been proposed for statin-induced myopathy [7].…”

Section: Introductionmentioning

confidence: 99%

Structural Changes in the Skeletal Muscle Fiber of Adult Male Albino Rat Following Atorvastatin Treatment; the Possible Mechanisms of Atorvastatin Induced Myotoxicity

Mokhmer¹,

Saber²,

Hamouda³

et al. 2017

J Cytol Histol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Structural Changes in the Skeletal Muscle Fiber of Adult Male Albino Rat Following Atorvastatin Treatment; the Possible Mechanisms of Atorvastatin Induced Myotoxicity

Mokhmer¹,

Saber²,

Hamouda³

et al. 2017

J Cytol Histol

View full text Add to dashboard Cite

show abstract

“…Statin therapy forms the mainstay basis of contemporary drug treatment of coronary artery diseases [1]. Most largescale trials have underscored the effectiveness of statins on morbidity and mortality in both primary and secondary prevention of cardiovascular events [2][3][4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

“…Most largescale trials have underscored the effectiveness of statins on morbidity and mortality in both primary and secondary prevention of cardiovascular events [2][3][4][5][6][7]. Evidence is accumulating that pleiotropic effects account for several therapeutic properties of these compounds [1,8,9]. This is strengthened by studies suggesting that statin treatment reduces cardiovascular events even in normocholesterolaemic patients and especially in those having normal low-density lipoprotein (LDL) cholesterol [10,11].…”

Section: Introductionmentioning

confidence: 99%

Atorvastatin therapy improves exercise oxygen uptake kinetics in post‐myocardial infarction patients

Tumminello¹,

Reina²,

Vicenzi³

et al. 2007

Eur J Clin Investigation

View full text Add to dashboard Cite

Background Statins represent a modern mainstay of the drug treatment of coronary artery disease and acute coronary syndromes. Reduced aerobic work performance and slowed VO 2 kinetics are established features of the clinical picture of post-myocardial infarction (MI) patients. We tested the hypothesis that statin therapy improves VO 2 exercise performance in normocholesterolaemic post-MI patients. Materials and methodsAccording to a double-blinded, randomized, crossover and placebocontrolled study design, in 18 patients with uncomplicated recent (3 days) MI we investigated the effects of atorvastatin (20 mg day − 1 ) on gas exchange kinetics by calculating VO 2 effective time constant (tau) during a 50-watt constant workload exercise, brachial artery flowmediated dilatation (FMD) as an index of endothelial function, left ventricular function (echocardiography) and C-reactive protein (CRP, as an index of inflammation). Atorvastatin or placebo was given for 3 months each.Results Atorvastatin therapy significantly improved exercise VO 2 tau and FMD, and reduced CRP levels. We did not observe changes in cardiac contractile function and relaxation properties during all study periods in either group. ConclusionsIn post-MI patients exercise performance is a potential additional target of benefits related to statin therapy. Endothelial function improvement is very likely implicated in this newly described therapeutic property.

show abstract

“…FCRs of VLDL-and LDL-apoB were significantly higher after atorvastatin treatment (7.2063.08 versus 5.2062.98 days 21 , P,0.05; 0.85160.772 versus 0.44660.232 days 2 1 , P,0.05), whereas their concentrations were lower compared with baseline. Accordingly, their residence times in plasma-being the inverse values of FCR-were significantly lower (0.14 versus 0.19 day for VLDL and 1.2 versus 2.2 days for LDL).…”

Section: Kinetics Of Apob-containing Lipoproteinsmentioning

confidence: 87%

Lipoprotein Kinetics in Male Hemodialysis Patients Treated with Atorvastatin

Schwaiger

Nakada

Berberich

et al. 2013

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryBackground and objectives In vivo metabolism of atherogenic apolipoprotein B (apoB)-containing lipoproteins is severely impaired in patients undergoing hemodialysis (HD), resulting in markedly prolonged residence times of these particles. It is unclear whether treatment with statins improves LDL kinetics in HD patients as is known for the general population. Therefore, this kinetic study assessed apoB-containing lipoproteins in these patients.Design, setting, participants, & measurements Kinetic measures were analyzed with stable-isotope technology in six men undergoing HD before and after 3 months of daily administration of 10 mg of atorvastatin. Patients were 18-65 years of age, had LDL cholesterol levels between 90 and 200 mg/dl, and had been treated with HD for .6 months. They consumed a standardized isocaloric diet for 3 days before analysis. Fractional catabolic rates (FCRs) and production rates of very-low-density lipoprotein (VLDL)-apoB, intermediate-density lipoproteinapoB, and LDL-apoB were determined using multicompartment modeling after plasma lipoprotein separation, precipitation of apoB, and determination of tracer-to-tracee ratios using mass spectrometry.Results Plasma concentrations of VLDL-and LDL-apoB were significantly lower (mean 6 SD, 7.7762.62 versus 11.2766.15 mg/dl, P,0.05; 56.9623.9 versus 84.0621.1 mg/dl, P=0.03) and their FCRs were significantly higher (7.2063.08 versus 5.2062.98 days 21 , P,0.05; 0.85160.772 versus 0.44660.232 days 21 , P,0.05) after 3 months of atorvastatin treatment. Accordingly, the residence times in plasma of VLDL-and LDL-apoB were significantly lower after treatment (0.14 versus 0.19 day and 1.2 versus 2.2 days, respectively). ConclusionLower plasma concentrations and improved kinetics of atherogenic lipoproteins were observed in HD patients after administration of low-dose atorvastatin.

show abstract

Update on Statins: 2003

Cited by 213 publications

References 66 publications

Structural Changes in the Skeletal Muscle Fiber of Adult Male Albino Rat Following Atorvastatin Treatment; the Possible Mechanisms of Atorvastatin Induced Myotoxicity

Structural Changes in the Skeletal Muscle Fiber of Adult Male Albino Rat Following Atorvastatin Treatment; the Possible Mechanisms of Atorvastatin Induced Myotoxicity

Atorvastatin therapy improves exercise oxygen uptake kinetics in post‐myocardial infarction patients

Lipoprotein Kinetics in Male Hemodialysis Patients Treated with Atorvastatin

Contact Info

Product

Resources

About